Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Recaticimab on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Recaticimab is a long-acting cholesterol-lowering injection for adults whose "bad" LDL cholesterol stays too high. It was developed in China by Jiangsu Hengrui Pharmaceuticals and is licensed through its subsidiary, Guangdong Hengrui Pharmaceutical Co., Ltd., under the brand name 艾心安®. Its main selling point is how rarely it is needed: one injection under the skin every four or every eight weeks.
China's National Medical Products Administration (NMPA) approved it in January 2025, alongside a cholesterol-lowering diet, for adults with:
It is a prescription heart and cholesterol medicine and should be used under a cardiologist, endocrinologist or lipid specialist.
The liver clears LDL cholesterol from the blood using LDL receptors. A protein called PCSK9 tags these receptors for destruction, so fewer are left to do the job. Recaticimab is a humanised monoclonal antibody that grabs PCSK9 and stops it binding to the receptors. More receptors survive, and more LDL cholesterol is pulled out of the blood. Its antibody tail has been engineered so the body recycles it for longer, which is why the doses can be spaced weeks apart.
Three phase 3 trials in China, run by Hengrui with Chinese heart hospitals, support the approval:
Non-HDL cholesterol, ApoB and lipoprotein(a) also improved. These trials measured changes in cholesterol levels, not heart attacks or strokes.
The approved schedules in China are:
Each vial contains 150 mg of recaticimab. Your doctor will choose the schedule and check your lipid levels after a few weeks to see how well it is working.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Overall safety: in the trials, side effects were broadly similar to placebo. In REMAIN-2, treatment-related side effects were reported in 28.5% of people on recaticimab and 26.6% on placebo, and serious treatment-related events in 0.4% of each group.
Statin rules still apply: when used with a statin, the statin's own precautions continue, including liver and muscle checks. Information on use in pregnancy, breastfeeding and children was not available in the sources we reviewed, so discuss this with your doctor before starting.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The injection can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. Because it is a long-term treatment, we can plan supply several doses at a time so there is no gap between injections.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The vials are kept in their sealed original packs, stored as directed on the Chinese pack, and travel under temperature-controlled shipping. Each vial holds 150 mg, so one vial covers a 4-weekly dose and two vials cover an 8-weekly dose. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating clinic on a valid specialist's prescription.
Lipid and heart clinics in Delhi see patients from across North India, and our New Delhi dispatch point means short delivery times.
Cardiologists in Mumbai can request the medicine for a named patient, with supply planned around the 4- or 8-week schedule.
Patients in Bangalore can have the vials delivered to their clinic once the prescription and lipid report are checked.
A long-standing centre for preventive cardiology in South India, used to managing imported medicines for individual patients.
Doctors in Hyderabad can share the prescription and latest lipid profile with us to start the import.
For Kolkata and the eastern states, we time deliveries so the next dose arrives before it is due.
Patients in Pune can use the same documented import route, with updates shared at every step.
Specialists in Ahmedabad treating familial or hard-to-control high cholesterol can arrange access for a named patient.
Patients in Rajasthan can receive the medicine without travelling, as long as the import is in their name.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the patient or the treating clinic.
We coordinate delivery for patients treated at public and private heart hospitals across Uttar Pradesh.
Patients across Kerala can have their doses delivered to their clinic in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
